Chris Chapman is listed as an executive officer and director on 6 SEC Form D filings by 3 issuers between Aug 2022 and May 2024: TNF Pharmaceuticals, Inc. (New York, NY — pharmaceuticals — 2022–2024; $26.9M reported sold to 56 investors), Mira1a Therapeutics, Inc. (Baltimore, MD — pharmaceuticals — 2022; $6.51M reported sold to 76 investors) and Telomir Pharmaceuticals, Inc. (Tampa, FL — pharmaceuticals — 2023; $1M reported sold to 10 investors).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as executive officer and director, over about 2 years. Across those companies the filings report $34.4M sold in total.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 9 bankruptcy cases matching the name listed in Key records below.
What this means 9 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 6 public filings for Chris Chapman and found 9 differences, 1 worth asking the sponsor about: Form D filed 265 days after the first sale; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.